Chronobiologically Explored Effects of Telmisartan

References

• Cornélissen G, Schwartzkopff O, Halberg F, Otsuka K, Watanabe Y. 7-Day ambulatory monitoring for adults with hypertension and diabetes [letter]. Am J Kidney Dis 2001; 37:878.
   PubMed Web of Science ®Google Scholar
• Halberg F, Cornélissen G, Halberg J, Fink H, Chen C-H, Otsuka K, Watanabe Y, Kumagai Y, Syutkina E V, Kawasaki T, Uezono K, Zhao Z Y, Schwartzkopff O. Circadian Hyper-Amplitude-Tension, CHAT: a disease risk syndrome of anti-aging medicine. J Anti-Aging Med 1998; 1:239–259.
   Google Scholar
• Otsuka K, Cornélissen G, Halberg F, Oehlert G. Excessive circadian amplitude of blood pressure increases risk of ischemic stroke and nephropathy. J Med Eng Technol 1997; 21:23–30. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Shinagawa M, Kubo Y, Otsuka K, Ohkawa S, Cornélissen G, Halberg F. Impact of circadian amplitude and chronotherapy: relevance to prevention and treatment of stroke. Biomed Pharmacother 2001; 55(suppl 1):125–132.
   PubMedGoogle Scholar
• Cavallini M, Halberg F, Cornélissen G, Enrichens F, Margarit C. Organ transplantation and broader chronotherapy with implantable pump and computer programs for marker rhythm assessment. J Control Release 1986; 3:3–13. [CROSSREF]
   Google Scholar
• Neutel J M. Use of ambulatory monitoring to evaluate the selective angiotensin II receptor antagonist, telmisartan, and other antihypertensive drugs. Blood Press Monit 2000; 5(suppl 1):S35–S40. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Kulbertus H. Pharma-clinics. Medication of the month. Telmisartan (Micardis). Rev Med Liège 2000; 55:57–60.
   PubMedGoogle Scholar
• Teichholz L E, Kreulen T, Herman M V, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976; 37:7–11. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kolosova R. Dopplerovske vysetrení renálních tepen. Kardiol Rev 2001; 2:70–74. [CSA]
   Google Scholar
• Ripolles T, Aliaga R, Morote V, Lonjedo E, Delgado F, Martinez M J, Vilar J. Utility ofintrarenal Doppler ultrasound in the diagnosis of renal artery stenosis. Eur J Radiol 2001; 40:54–63. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cornélissen G, Halberg F. Chronomedicine. In: Armitage P, Colton T, ed. Encyclopedia of Biostatistics. Vol. 1. ChichesterUK: J. Wiley, 1998:642–649.
   Google Scholar
• Halberg F. Chronobiology. Annu Rev Physiol 1969; 31:675–725. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Güllner H G, Bartter F C, Halberg F. Timing antihypertensive medication. Lancet 1979; 2(8141):527. [CSA]
   PubMed Web of Science ®Google Scholar
• Cornélissen G, Zaslavskaya R M, Kumagai Y, Romanov Y, Halberg F. Chronopharmacologic issues in space. J Clin Pharmacol 1994; 34:543–551. [CSA]
   PubMed Web of Science ®Google Scholar
• Little J, Sanchez de la Pena S, Cornélissen G, Abramowitz P, Tuna N, Halberg F. Longitudinal chronobiologic Blood Press Monit for assessing the need and timing of antihypertensive treatment. Prog Clin Biol Res 1990; 341B:601–611. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Cornélissen G, Halberg F, Prikryl P, Dankova E, Siegelova J, Dusek J. International Womb-to-Tomb Chronome Study Group: Prophylactic aspirin treatment: the merits of timing. JAMA 1991; 266:3128–3129. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hermida R C, Ayala D, Fernandez J R, Mojon A, Alonso I, Silva I, Ucieda R, Codesido J, Iglesias M. Administration time-dependent effects of aspirin in women at differing risk for preeclampsia. Hypertension 1999; 34(4 Part 2 suppl S):1016–1023. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Siegelova J, Cornélissen G, Dusek J, Prikryl P, Fiser B, Dankova E, Tocci A, Ferrazzani S, Hermida R, Bingham C, Hawkins D, Halberg F. Aspirin and the blood pressure and heart rate of healthy women. Policlinico (Chrono) 1995; 1(2):43–49. [CSA]
   Google Scholar
• Watanabe Y, Cornélissen G, Otsuka K, Siegelova J, Jancik J, Halberg F. Longitudinal ambulatory blood pressure monitoring for a sequential chronobiologic assessment of losartan effect. Scripta Med (Brno) 2002; 75:129–134. [CSA]
   Google Scholar
• Dahlof B, Devereux R B, Julius S, Kjeldsen S E, Beevers G, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm L H, Nieminen M S, Omvik P, Oparil S, Wedel H. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 1998; 32:989–997. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wilson T W, Lacourciere Y, Barnes C C. The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. Canadian Cozaar Hyzaar Amlodipine Trial Study Group. CMAJ 1998; 159:469–476. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Farsang C, Garcia-Puig J, Niegowska J, Baiz A Q, Vrijens F, Bortman G. The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group. J Hypertens 2000; 18:795–801. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Almazov V A, Shlyakhto E V, Konrady A O, Macsimova T A, Zaharov D V, Rudomanov O G. Correction of hypertensive cardiac remodeling: comparison of different antihypertensive therapies. Med Sci Monit 2000; 6:309–313. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Omvik P, Gerdts E, Myking O L, Lund-Johansen P. Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension. Am Heart J 2000; 140:624–630. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tedesco M A, Ratti G, Aquino D, Limongelli G, di Salvo G, Mennella S, Galzerano D, Iarussi D, Iacono A. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens 1998; 12:505–510. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Schillaci G, Reboldi G P, Sacchi N, Bruni B, Benemio G, Porcellati C. Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: a case-control study. Blood Press Monit 2000; 5:187–193. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux R B, Kjeldsen S E, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm L H, Nieminen M S, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:995–1003., [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lindholm L H, Ibsen H, Dahlof B, Devereux R B, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen S E, Kristiansson K, Lederballe-Pedersen O, Nieminen M S, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:1004–1010. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Levy P J, Yunis C, Owen J, Brosnihan K B, Smith R, Ferrario C M. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000; 86:1188–1192. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Prasad A, Koh K K, Schenke W H, Mincemoyer R, Csako G, Fleischer T A, Brown M, Selvaggi T A, Quyyumi A A. Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. Am Heart J 2001; 142:248–253. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sica D A, Halstenson C E, Gehr T W, Keane W F. Pharmacokinetics and blood pressure response of losartan in end-stage renal disease. Clin Pharmacokinet 2000; 38:519–526. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Manolis A J, Grossman E, Jelakovic B, Jacovides A, Bernhardi D C, Cabrera W J, Watanabe L A, Barragan J, Matadamas N, Mendiola A, Woo K S, Zhu J R, Mejia A D, Bunt T, Dumortier T, Smith R D. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther 2000; 22:1186–1203. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Monterroso V H, Rodriguez Chavez V, Carbajal E T, Vogel D R, Aroca Martinez G J, Garcia L H, Cuevas J H, Lara Teran J, Hitzenberger G, Leao Neves P, Middlemost S J, Dumortier T, Bunt A M, Smith R D. Use of ambulatory Blood Press Monit to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan Trial Investigators. Adv Ther 2000; 17:117–131. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lozano J V, Llisterri J L, Aznar J, Redon J, Spanish Working Group. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001; 16(suppl 1):85–89. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Brenner B M, Cooper M E, de Zeeuw D, Keane W F, Mitch W E, Parving H H, Remuzzi G, Snapinn S M, Zhang Z, Shahinfar S, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861–869. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bingham C, Arbogast B, Cornélissen Guillaume G, Lee J K, Halberg F. Inferential statistical methods for estimating and comparing cosinor parameters. Chronobiologia 1982; 9:397–439. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Hawkins D M. Self-starting CUSUM charts for location and scale. Statistician 1987; 36:299–315. [CSA]
   Google Scholar